The road from discovery to clinic: Adiponectin as a biomarker of metabolic status

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

Original languageEnglish (US)
Pages (from-to)592-595
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume86
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Adiponectin
Biomarkers
Peroxisome Proliferator-Activated Receptors
Drug Industry
Adipocytes
Life Style
Hormones
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{22e9ee34d3fa40d5954580337c4d84c8,
title = "The road from discovery to clinic: Adiponectin as a biomarker of metabolic status",
abstract = "Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.",
author = "Kusminski, {C. M.} and Scherer, {P. E.}",
year = "2009",
doi = "10.1038/clpt.2009.155",
language = "English (US)",
volume = "86",
pages = "592--595",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The road from discovery to clinic

T2 - Adiponectin as a biomarker of metabolic status

AU - Kusminski, C. M.

AU - Scherer, P. E.

PY - 2009

Y1 - 2009

N2 - Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

AB - Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

UR - http://www.scopus.com/inward/record.url?scp=70450134177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450134177&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.155

DO - 10.1038/clpt.2009.155

M3 - Article

C2 - 19915603

AN - SCOPUS:70450134177

VL - 86

SP - 592

EP - 595

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -